Cargando…
Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity
PURPOSE: The selective elimination of cancer stem cells (CSCs) in tumor patients is a crucial goal because CSCs cause drug refractory relapse. To improve the current conventional bispecific immune-engager platform, a 16133 bispecific natural killer (NK) cell engager (BiKE), consisting of scFvs bindi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654165/ https://www.ncbi.nlm.nih.gov/pubmed/28231426 http://dx.doi.org/10.4143/crt.2016.491 |
_version_ | 1783273360756572160 |
---|---|
author | Schmohl, Jörg U. Felices, Martin Oh, Felix Lenvik, Alexander J. Lebeau, Aaron M. Panyam, Jayanth Miller, Jeffrey S. Vallera, Daniel A. |
author_facet | Schmohl, Jörg U. Felices, Martin Oh, Felix Lenvik, Alexander J. Lebeau, Aaron M. Panyam, Jayanth Miller, Jeffrey S. Vallera, Daniel A. |
author_sort | Schmohl, Jörg U. |
collection | PubMed |
description | PURPOSE: The selective elimination of cancer stem cells (CSCs) in tumor patients is a crucial goal because CSCs cause drug refractory relapse. To improve the current conventional bispecific immune-engager platform, a 16133 bispecific natural killer (NK) cell engager (BiKE), consisting of scFvs binding FcγRIII (CD16) on NK cells and CD133 on carcinoma cells, was first synthesized and a modified interleukin (IL)-15 crosslinker capable of stimulating NK effector cells was introduced. MATERIALS AND METHODS: DNA shuffling and ligation techniques were used to assemble and synthesize the 1615133 trispecific NK cell engager (TriKE). The construct was tested for its specificity using flow cytometry, cytotoxic determinations using chromium release assays, and lytic degranulation. IL-15–mediated expansion was measured using flow-based proliferation assays. The level of interferon (IFN)-γ release was measured because of its importance in the anti-cancer response. RESULTS: 1615133 TriKE induced NK cell–mediated cytotoxicity and NK expansion far greater than that achieved with BiKE devoid of IL-15. The drug binding and induction of cytotoxic degranulation was CD133(+) specific and the anti-cancer activity was improved by integrating the IL-15 cross linker. The NK cell–related cytokine release measured by IFN-γ detection was higher than that of BiKE. NK cytokine release studies showed that although the IFN-γ levels were elevated, they did not approach the levels achieved with IL-12/IL-18, indicating that release was not at the supraphysiologic level. CONCLUSION: 1615133 TriKE enhances the NK cell anti-cancer activity and provides a self-sustaining mechanism via IL-15 signaling. By improving the NK cell performance, the new TriKE represents a highly active drug against drug refractory relapse mediated by CSCs. |
format | Online Article Text |
id | pubmed-5654165 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Korean Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-56541652017-10-25 Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity Schmohl, Jörg U. Felices, Martin Oh, Felix Lenvik, Alexander J. Lebeau, Aaron M. Panyam, Jayanth Miller, Jeffrey S. Vallera, Daniel A. Cancer Res Treat Original Article PURPOSE: The selective elimination of cancer stem cells (CSCs) in tumor patients is a crucial goal because CSCs cause drug refractory relapse. To improve the current conventional bispecific immune-engager platform, a 16133 bispecific natural killer (NK) cell engager (BiKE), consisting of scFvs binding FcγRIII (CD16) on NK cells and CD133 on carcinoma cells, was first synthesized and a modified interleukin (IL)-15 crosslinker capable of stimulating NK effector cells was introduced. MATERIALS AND METHODS: DNA shuffling and ligation techniques were used to assemble and synthesize the 1615133 trispecific NK cell engager (TriKE). The construct was tested for its specificity using flow cytometry, cytotoxic determinations using chromium release assays, and lytic degranulation. IL-15–mediated expansion was measured using flow-based proliferation assays. The level of interferon (IFN)-γ release was measured because of its importance in the anti-cancer response. RESULTS: 1615133 TriKE induced NK cell–mediated cytotoxicity and NK expansion far greater than that achieved with BiKE devoid of IL-15. The drug binding and induction of cytotoxic degranulation was CD133(+) specific and the anti-cancer activity was improved by integrating the IL-15 cross linker. The NK cell–related cytokine release measured by IFN-γ detection was higher than that of BiKE. NK cytokine release studies showed that although the IFN-γ levels were elevated, they did not approach the levels achieved with IL-12/IL-18, indicating that release was not at the supraphysiologic level. CONCLUSION: 1615133 TriKE enhances the NK cell anti-cancer activity and provides a self-sustaining mechanism via IL-15 signaling. By improving the NK cell performance, the new TriKE represents a highly active drug against drug refractory relapse mediated by CSCs. Korean Cancer Association 2017-10 2017-02-20 /pmc/articles/PMC5654165/ /pubmed/28231426 http://dx.doi.org/10.4143/crt.2016.491 Text en Copyright © 2017 by the Korean Cancer Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Schmohl, Jörg U. Felices, Martin Oh, Felix Lenvik, Alexander J. Lebeau, Aaron M. Panyam, Jayanth Miller, Jeffrey S. Vallera, Daniel A. Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity |
title | Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity |
title_full | Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity |
title_fullStr | Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity |
title_full_unstemmed | Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity |
title_short | Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity |
title_sort | engineering of anti-cd133 trispecific molecule capable of inducing nk expansion and driving antibody-dependent cell-mediated cytotoxicity |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654165/ https://www.ncbi.nlm.nih.gov/pubmed/28231426 http://dx.doi.org/10.4143/crt.2016.491 |
work_keys_str_mv | AT schmohljorgu engineeringofanticd133trispecificmoleculecapableofinducingnkexpansionanddrivingantibodydependentcellmediatedcytotoxicity AT felicesmartin engineeringofanticd133trispecificmoleculecapableofinducingnkexpansionanddrivingantibodydependentcellmediatedcytotoxicity AT ohfelix engineeringofanticd133trispecificmoleculecapableofinducingnkexpansionanddrivingantibodydependentcellmediatedcytotoxicity AT lenvikalexanderj engineeringofanticd133trispecificmoleculecapableofinducingnkexpansionanddrivingantibodydependentcellmediatedcytotoxicity AT lebeauaaronm engineeringofanticd133trispecificmoleculecapableofinducingnkexpansionanddrivingantibodydependentcellmediatedcytotoxicity AT panyamjayanth engineeringofanticd133trispecificmoleculecapableofinducingnkexpansionanddrivingantibodydependentcellmediatedcytotoxicity AT millerjeffreys engineeringofanticd133trispecificmoleculecapableofinducingnkexpansionanddrivingantibodydependentcellmediatedcytotoxicity AT valleradaniela engineeringofanticd133trispecificmoleculecapableofinducingnkexpansionanddrivingantibodydependentcellmediatedcytotoxicity |